Literature DB >> 18834994

A cross-sectional study for glucose intolerance of myotonic dystrophy.

Tsuyoshi Matsumura1, Hiromi Iwahashi, Tohru Funahashi, Masanori P Takahashi, Tomoko Saito, Kumiko Yasui, Toshio Saito, Akinori Iyama, Keiko Toyooka, Harutoshi Fujimura, Susumu Shinno.   

Abstract

We made a cross-sectional study to analyze glucose intolerance of myotonic dystrophy type 1 (DM1) with several examination including oral glucose tolerance test (OGTT), insulin tolerance test (ITT) and adiponectin. Ninety-five DM1 patients participated in this study. Health examination data from general people were used as controls. In DM1, homeostasis model assessment-insulin resistance (HOMA-IR) was higher than control even in the lowest fasting blood sugar (FBS) stage (<80 mg/dl) and insulin sensitivity assessed by ITT was low regardless of their FBS. Insulinogenic index of DM1 was positively correlated to HOMA-IR. Insulinogenic index and sum of IRI in OGTT were markedly elevated in the lowest FBS stage and declined along with elevation of FBS. Consequently, as many as 13.3% of DM1 patients with 90-110 mg/dl of FBS exhibited DM pattern, while only 1.9% in control. Adiponectin was higher in DM1 than control. Although age correlated with adiponectin in both control and DM1, its impact was stronger in DM1. DM1 predisposes insulin resistance and compensatory hyperinsulinemia exist even in patients with low FBS. We should pay attention to glucose intolerance of DM1 patients earlier than that of the general population. It seemed that 90 mg/dl of FBS is an important index as an indication of careful managements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18834994     DOI: 10.1016/j.jns.2008.08.037

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study.

Authors:  M Spaziani; A Semeraro; E Bucci; F Rossi; M Garibaldi; M A Papassifachis; C Pozza; A Anzuini; A Lenzi; G Antonini; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

2.  Muscular dystrophies at different ages: metabolic and endocrine alterations.

Authors:  Oriana Del Rocío Cruz Guzmán; Ana Laura Chávez García; Maricela Rodríguez-Cruz
Journal:  Int J Endocrinol       Date:  2012-06-03       Impact factor: 3.257

3.  Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre cohort follow-up study.

Authors:  Mark J Hamilton; Yvonne Robb; Sarah Cumming; Helen Gregory; Alexis Duncan; Monika Rahman; Anne McKeown; Catherine McWilliam; John Dean; Alison Wilcox; Maria E Farrugia; Anneli Cooper; Josephine McGhie; Berit Adam; Richard Petty; Cheryl Longman; Iain Findlay; Alan Japp; Darren G Monckton; Martin A Denvir
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 4.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

Review 5.  Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin.

Authors:  Tiago Mateus; Filipa Martins; Alexandra Nunes; Maria Teresa Herdeiro; Sandra Rebelo
Journal:  Int J Environ Res Public Health       Date:  2021-02-12       Impact factor: 3.390

6.  Dysfunctional muscle and liver glycogen metabolism in mdx dystrophic mice.

Authors:  David I Stapleton; Xianzhong Lau; Marcelo Flores; Jennifer Trieu; Stefan M Gehrig; Annabel Chee; Timur Naim; Gordon S Lynch; René Koopman
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 7.  Core Clinical Phenotypes in Myotonic Dystrophies.

Authors:  Stephan Wenninger; Federica Montagnese; Benedikt Schoser
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

8.  A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size.

Authors:  Yara Eid Mutlak; Dina Aweida; Alexandra Volodin; Bar Ayalon; Nitsan Dahan; Anna Parnis; Shenhav Cohen
Journal:  Nat Commun       Date:  2020-03-13       Impact factor: 14.919

Review 9.  Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences.

Authors:  Thuy-Hang Nguyen; Stephanie Conotte; Alexandra Belayew; Anne-Emilie Declèves; Alexandre Legrand; Alexandra Tassin
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 10.  Targeting Myotonic Dystrophy Type 1 with Metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Ander Matheu; Adolfo López de Munain
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.